Cardica Announces Commercial Availability of White Cartridge for MicroCutter XCHANGE™ 30 Cutting/Stapling Device

 Cardica Announces Commercial Availability of White Cartridge for MicroCutter
                     XCHANGE™ 30 Cutting/Stapling Device

PR Newswire

REDWOOD CITY, Calif., Dec. 11, 2013

REDWOOD CITY, Calif., Dec. 11, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq:
CRDC) today announced the commercial availability of the white cartridge for
its MicroCutter XCHANGE™ 30 in Europe. Following extensive product testing to
confirm reliability and functionality, Cardica shipped its initial commercial
batches of white cartridges to its European distributors. The white cartridge
is designed to be used with the MicroCutter XCHANGE 30 to staple blood vessels
and other small tissue structures during open and laparoscopic surgical
procedures.

"Our team worked tirelessly to develop, test and retest the white cartridge
prior to shipping to our commercial accounts," said Bernard A. Hausen, M.D.,
Ph.D., president and CEO of Cardica. "The achievement of this milestone opens
up the market opportunity for Cardica, as the XCHANGE 30 is now ideally suited
to facilitate a wide range of surgical procedures including pediatric cases,
and resections and transections of numerous organs."

AboutCardica
Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to minimize operating time and enable minimally-invasive
and robot-assisted surgeries. Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 47,700 units throughout the world. In
addition,Cardicais developing the Cardica^® MicroCutter XCHANGE™ 30, a
cartridge-based microcutter device with a five-millimeter shaft diameter, and
the Cardica^® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device
with an eight-millimeter shaft. Both MicroCutter devices are designed to be
used in a variety of procedures, including bariatric, colorectal, thoracic and
general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products
require 510(k) review and are not yet commercially available in the U.S.

Forward-Looking Statements
The statement in this press release regarding Cardica's belief that the
availability of the white cartridge opens up the market opportunity for
Cardica is a "forward-looking statement." There are a number of important
factors that could cause Cardica's results to differ materially from those
indicated by these forward-looking statements, including: that Cardica may not
be successful in its efforts to further develop or commercialize the XCHANGE
30 due to unanticipated technical or other difficulties; that the XCHANGE 30
may face unanticipated development, regulatory, or manufacturing delays; that
Cardica's intellectual property rights may not provide adequate protection to
enable further development of the XCHANGE 30; that surgeons may not use the
XCHANGE 30 correctly, which could cause unfavorable results that may impair
the acceptance of the XCHANGE 30 by other surgeons; and that Cardica may not
have sufficient funds to develop the XCHANGE 30, as well as other risks
detailed from time to time in Cardica's reports filed with the U.S. Securities
and Exchange Commission, including its Quarterly Report on Form 10-Q for the
quarter endedSeptember 30, 2013, under the caption "Risk Factors." Cardica
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein. You
are encouraged to read Cardica's reports filed with the U.S. Securities and
Exchange Commission, available at www.sec.gov.

SOURCE Cardica

Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
+1-650-331-7133, investors@cardica.com
 
Press spacebar to pause and continue. Press esc to stop.